The HIGH BCR-ABL1 GENE PERCENTAGE AT TIME OF PRESENTATION: A TOOL TO PREDICT FAILURE IN ACHIEVING EARLY MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA (CML): A TERTIARY CARE CENTER EXPERIENCE

Objective: To determine the relationship of baseline quantitative BCR ABL1 gene percentage and therapeutic response i.e. Early Molecular Response (EMR) at 3 months with first generation Tyrosine kinase inhibitors (Imatinib) in patients with Chronic Myeloid Leukemia (CML) in chronic phase (CP). St...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Amjad Khan, Riaz Ahmed, Sarah Fatimah, Muhammad Nadeem, Shama Iqbal, Sayed Tanveer Abbas Gilani, Huma Amjad
Formato:	article
Lenguaje:	EN
Publicado:	Army Medical College Rawalpindi 2021
Materias:	chronic myeloid leukemia early molecular response imatinib Medicine R Medicine (General) R5-920
Acceso en línea:	https://doi.org/10.51253/pafmj.v71iSuppl-1.3891 https://doaj.org/article/846cf15589294effabd70c5c81935f9c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:846cf15589294effabd70c5c81935f9c
record_format	dspace
spelling	oai:doaj.org-article:846cf15589294effabd70c5c81935f9c2021-12-02T19:11:53ZThe HIGH BCR-ABL1 GENE PERCENTAGE AT TIME OF PRESENTATION: A TOOL TO PREDICT FAILURE IN ACHIEVING EARLY MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA (CML): A TERTIARY CARE CENTER EXPERIENCEhttps://doi.org/10.51253/pafmj.v71iSuppl-1.38910030-96482411-8842https://doaj.org/article/846cf15589294effabd70c5c81935f9c2021-01-01T00:00:00Zhttps://pafmj.org/index.php/PAFMJ/article/view/3891https://doaj.org/toc/0030-9648https://doaj.org/toc/2411-8842Objective: To determine the relationship of baseline quantitative BCR ABL1 gene percentage and therapeutic response i.e. Early Molecular Response (EMR) at 3 months with first generation Tyrosine kinase inhibitors (Imatinib) in patients with Chronic Myeloid Leukemia (CML) in chronic phase (CP). Study Design: Prospective observational study. Place and Duration of Study: Combined Military Hospital, Rawalpindi, Pakistan, and Armed Forces Institute of Pathology Rawalpindi, Pakistan from Oct 2017 to Oct 2019. Methodology: One hundred and seventy patients, 18 years of age or older with newly diagnosed Chronic Myeloid Leukemia (CML) in chronic phase (CP) with quantitative baseline BCR-ABL (IS) transcript were included in the study. All enrolled patients were placed on Imatinib therapy (400 mg/day) and Reverse transcription polymerase chain reaction (RT-PCR) for BCR ABL transcript was repeated at 3 months to document EMR (BCR-ABL (IS) <10%). Patients who were in accelerated/blast phase, or already taking any Tyrosine Kinase Inhibitors (TKI) or chemotherapy were excluded from the study. Results: In our study 101 (59.4%) patients achieved early molecular response. Out of these 80 (70.8%) patients with BCR-ABL<50% at baseline value showed early molecular response. However, only 21 (36.8%) with BCRABL >50% at baseline achieved early molecular response (p-value <0.001). Conclusion: A significant number of patients achieved early molecular response with Imatinib therapy that had BCR ABL below 50%, however those with baseline BCR ABL >50%, the rate of EMR was comparatively lower.Amjad KhanRiaz AhmedSarah FatimahMuhammad NadeemShama IqbalSayed Tanveer Abbas GilaniHuma AmjadArmy Medical College Rawalpindiarticlechronic myeloid leukemiaearly molecular responseimatinibMedicineRMedicine (General)R5-920ENPakistan Armed Forces Medical Journal, Vol 71, Iss SUPPL-1, Pp 71-75 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	chronic myeloid leukemia early molecular response imatinib Medicine R Medicine (General) R5-920
spellingShingle	chronic myeloid leukemia early molecular response imatinib Medicine R Medicine (General) R5-920 Amjad Khan Riaz Ahmed Sarah Fatimah Muhammad Nadeem Shama Iqbal Sayed Tanveer Abbas Gilani Huma Amjad The HIGH BCR-ABL1 GENE PERCENTAGE AT TIME OF PRESENTATION: A TOOL TO PREDICT FAILURE IN ACHIEVING EARLY MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA (CML): A TERTIARY CARE CENTER EXPERIENCE
description	Objective: To determine the relationship of baseline quantitative BCR ABL1 gene percentage and therapeutic response i.e. Early Molecular Response (EMR) at 3 months with first generation Tyrosine kinase inhibitors (Imatinib) in patients with Chronic Myeloid Leukemia (CML) in chronic phase (CP). Study Design: Prospective observational study. Place and Duration of Study: Combined Military Hospital, Rawalpindi, Pakistan, and Armed Forces Institute of Pathology Rawalpindi, Pakistan from Oct 2017 to Oct 2019. Methodology: One hundred and seventy patients, 18 years of age or older with newly diagnosed Chronic Myeloid Leukemia (CML) in chronic phase (CP) with quantitative baseline BCR-ABL (IS) transcript were included in the study. All enrolled patients were placed on Imatinib therapy (400 mg/day) and Reverse transcription polymerase chain reaction (RT-PCR) for BCR ABL transcript was repeated at 3 months to document EMR (BCR-ABL (IS) <10%). Patients who were in accelerated/blast phase, or already taking any Tyrosine Kinase Inhibitors (TKI) or chemotherapy were excluded from the study. Results: In our study 101 (59.4%) patients achieved early molecular response. Out of these 80 (70.8%) patients with BCR-ABL<50% at baseline value showed early molecular response. However, only 21 (36.8%) with BCRABL >50% at baseline achieved early molecular response (p-value <0.001). Conclusion: A significant number of patients achieved early molecular response with Imatinib therapy that had BCR ABL below 50%, however those with baseline BCR ABL >50%, the rate of EMR was comparatively lower.
format	article
author	Amjad Khan Riaz Ahmed Sarah Fatimah Muhammad Nadeem Shama Iqbal Sayed Tanveer Abbas Gilani Huma Amjad
author_facet	Amjad Khan Riaz Ahmed Sarah Fatimah Muhammad Nadeem Shama Iqbal Sayed Tanveer Abbas Gilani Huma Amjad
author_sort	Amjad Khan
title	The HIGH BCR-ABL1 GENE PERCENTAGE AT TIME OF PRESENTATION: A TOOL TO PREDICT FAILURE IN ACHIEVING EARLY MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA (CML): A TERTIARY CARE CENTER EXPERIENCE
title_short	The HIGH BCR-ABL1 GENE PERCENTAGE AT TIME OF PRESENTATION: A TOOL TO PREDICT FAILURE IN ACHIEVING EARLY MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA (CML): A TERTIARY CARE CENTER EXPERIENCE
title_full	The HIGH BCR-ABL1 GENE PERCENTAGE AT TIME OF PRESENTATION: A TOOL TO PREDICT FAILURE IN ACHIEVING EARLY MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA (CML): A TERTIARY CARE CENTER EXPERIENCE
title_fullStr	The HIGH BCR-ABL1 GENE PERCENTAGE AT TIME OF PRESENTATION: A TOOL TO PREDICT FAILURE IN ACHIEVING EARLY MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA (CML): A TERTIARY CARE CENTER EXPERIENCE
title_full_unstemmed	The HIGH BCR-ABL1 GENE PERCENTAGE AT TIME OF PRESENTATION: A TOOL TO PREDICT FAILURE IN ACHIEVING EARLY MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA (CML): A TERTIARY CARE CENTER EXPERIENCE
title_sort	high bcr-abl1 gene percentage at time of presentation: a tool to predict failure in achieving early molecular response in chronic myeloid leukemia (cml): a tertiary care center experience
publisher	Army Medical College Rawalpindi
publishDate	2021
url	https://doi.org/10.51253/pafmj.v71iSuppl-1.3891 https://doaj.org/article/846cf15589294effabd70c5c81935f9c
work_keys_str_mv	AT amjadkhan thehighbcrabl1genepercentageattimeofpresentationatooltopredictfailureinachievingearlymolecularresponseinchronicmyeloidleukemiacmlatertiarycarecenterexperience AT riazahmed thehighbcrabl1genepercentageattimeofpresentationatooltopredictfailureinachievingearlymolecularresponseinchronicmyeloidleukemiacmlatertiarycarecenterexperience AT sarahfatimah thehighbcrabl1genepercentageattimeofpresentationatooltopredictfailureinachievingearlymolecularresponseinchronicmyeloidleukemiacmlatertiarycarecenterexperience AT muhammadnadeem thehighbcrabl1genepercentageattimeofpresentationatooltopredictfailureinachievingearlymolecularresponseinchronicmyeloidleukemiacmlatertiarycarecenterexperience AT shamaiqbal thehighbcrabl1genepercentageattimeofpresentationatooltopredictfailureinachievingearlymolecularresponseinchronicmyeloidleukemiacmlatertiarycarecenterexperience AT sayedtanveerabbasgilani thehighbcrabl1genepercentageattimeofpresentationatooltopredictfailureinachievingearlymolecularresponseinchronicmyeloidleukemiacmlatertiarycarecenterexperience AT humaamjad thehighbcrabl1genepercentageattimeofpresentationatooltopredictfailureinachievingearlymolecularresponseinchronicmyeloidleukemiacmlatertiarycarecenterexperience AT amjadkhan highbcrabl1genepercentageattimeofpresentationatooltopredictfailureinachievingearlymolecularresponseinchronicmyeloidleukemiacmlatertiarycarecenterexperience AT riazahmed highbcrabl1genepercentageattimeofpresentationatooltopredictfailureinachievingearlymolecularresponseinchronicmyeloidleukemiacmlatertiarycarecenterexperience AT sarahfatimah highbcrabl1genepercentageattimeofpresentationatooltopredictfailureinachievingearlymolecularresponseinchronicmyeloidleukemiacmlatertiarycarecenterexperience AT muhammadnadeem highbcrabl1genepercentageattimeofpresentationatooltopredictfailureinachievingearlymolecularresponseinchronicmyeloidleukemiacmlatertiarycarecenterexperience AT shamaiqbal highbcrabl1genepercentageattimeofpresentationatooltopredictfailureinachievingearlymolecularresponseinchronicmyeloidleukemiacmlatertiarycarecenterexperience AT sayedtanveerabbasgilani highbcrabl1genepercentageattimeofpresentationatooltopredictfailureinachievingearlymolecularresponseinchronicmyeloidleukemiacmlatertiarycarecenterexperience AT humaamjad highbcrabl1genepercentageattimeofpresentationatooltopredictfailureinachievingearlymolecularresponseinchronicmyeloidleukemiacmlatertiarycarecenterexperience
_version_	1718377098839588864

The HIGH BCR-ABL1 GENE PERCENTAGE AT TIME OF PRESENTATION: A TOOL TO PREDICT FAILURE IN ACHIEVING EARLY MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA (CML): A TERTIARY CARE CENTER EXPERIENCE

Ejemplares similares